Clinical Trial Update: Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Copper-64 SAR Bombesin in PSMA-negative prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Copper-64 SAR Bombesin

Snippet

Sponsor: St Vincent's Hospital, Sydney | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED